Taspoglutide, a Once-Weekly Human GLP-1 Analog, Reduces Appetite and Promotes Weight Loss in Patients With Type 2 Diabetes (T2D): Phase 3 Trial Versus Sitagliptin and Placebo (T-Emerge 4)

被引：0
|
作者：
Bergenstal, Richard
Forti, Adriana
Chiasson, Jean-Louis
Woloschak, Mike
Boldrin, Mark
Leiter, Lawrence
Balena, Raffaella
机构：
来源：
OBESITY | 2010年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S156 / S156
页数：1
相关论文
共 50 条
  • [41] Patient Factors Associated with GLP-1 Analog Use with and without Insulin in Type 2 Diabetes (T2D): Results from a Large Cohort Analysis
    Hirsch, Irl
    Silberman, Cheryl
    Calingaert, Brian
    DIABETES, 2010, 59 : A164 - A164
  • [42] Real-World Weight Change, Adherence, and Discontinuation among Type 2 Diabetes (T2D) Patients Initiating GLP-1 Receptor Agonists (GLP-1RAs) in the UK
    Weiss, Tracey
    Iglay, Kristy
    Carr, Richard D.
    Mishra, Ajay Pratap
    Yang, Lingfeng
    Rajpathak, Swapnil
    DIABETES, 2019, 68
  • [43] A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes
    Gantz, Ira
    Okamoto, Taro
    Ito, Yuka
    Okuyama, Kotoba
    O'Neill, Edward A.
    Kaufman, KeithD.
    Engel, Samuel S.
    Lai, Eseng
    DIABETES OBESITY & METABOLISM, 2017, 19 (11): : 1602 - 1609
  • [44] Real-World Adherence and Discontinuation of GLP-1 Receptor Agonist (GLP-1RA) Therapy in Type 2 Diabetes (T2D) Patients in the US
    Weiss, Tracey
    Iglay, Kristy
    Carr, Richard D.
    Mishra, Ajay Pratap
    Yang, Lingfeng
    Rajpathak, Swapnil
    DIABETES, 2019, 68
  • [45] The once-daily human GLP-1 analog liraglutide reduces body weight in subjects with type 2 diabetes, irrespective of body mass index at baseline
    Russell-Jones, David
    Shaw, Jonathan E.
    Brandle, Michael
    Matthews, David
    Frid, Anders
    Zdravkovic, Milan
    Schmitz, Ole
    DIABETES, 2008, 57 : A593 - A594
  • [46] THE DUAL GIP AND GLP-1 RECEPTOR AGONIST TIRZEPATIDE IMPROVES BIOMARKERS ASSOCIATED WITH CARDIOVASCULAR RISK IN PATIENTS WITH TYPE 2 DIABETES (T2D)
    Wilson, J.
    Nikooienejad, A.
    Lin, Y.
    Robins, D.
    Roell, W.
    Riesmeyer, J.
    Haupt, A.
    Duffin, K.
    Ruotolo, G.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 : A164 - A165
  • [47] Efficacy and Safety of Once-Weekly (QW) Albiglutide vs. Once-Daily (QD) Liraglutide in Type 2 Diabetes (T2D) Inadequately Controlled on Oral Agents: Harmony 7 Trial
    Pratley, Richard E.
    Barnett, Anthony
    Feinglos, Marc M.
    Harman-Boehm, Ilana
    Nauck, Michael
    Ovalle, Fernando
    Johnson, Susan
    Stewart, Murray
    Ye, June
    Rosenstock, Julio
    DIABETES, 2012, 61 : A240 - A241
  • [48] Harmony 8: Once Weekly (QW) GLP1 Agonist Albiglutide (Albi) vs. Sitagliptin (Sita) in Type 2 Diabetes (T2D) Pts With Renal Impairment (RI): Week 26 Results
    Leiter, Lawrence A.
    Carr, Molly C.
    Stewart, Murray
    Jonesleone, Angela R.
    Yang, Fred
    Handelsman, Yehuda
    DIABETES, 2013, 62 : A17 - A17
  • [49] ONCE-WEEKLY BASAL INSULIN FC (BIF) DEMONSTRATED SIMILAR GLYCEMIC CONTROL TO ONCE-DAILY INSULIN DEGLUDEC (DEG) IN INSULIN-NAIVE PATIENTS WITH TYPE 2 DIABETES (T2D)
    Bue-Valleskey, J.
    Kazda, C.
    Ma, C.
    Chien, J.
    Zhang, Q.
    Chigutsa, E.
    Landschulz, W.
    Swan, J.
    Haupt, A.
    Frias, J. P.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A193 - A193
  • [50] Dose-Response Improvements in Glycemic Control and Body Weight Reductions with HM11260C, a Once-Weekly GLP-1 Receptor Agonist with Liraglutide as Reference, in Type 2 Diabetes (T2DM)
    Rosenstock, Julio
    Kang, Jahoon
    Choi, Soomin
    Kim, Soojin
    Han, Oakpil
    Kil, Siyoen
    Gee, Kyuhoon
    Choi, In Young
    Kwon, Se Chang
    Trautmann, Michael
    Hompesch, Marcus
    DIABETES, 2015, 64 : A73 - A73
12345